Ionis (IONS) Q2 Revenue Soars 101%
Ionis Pharmaceuticals (NASDAQ:IONS), a biotechnology company focused on RNA-targeted therapeutics, reported its second quarter 2025 earnings on July 30, 2025. The headline news was a substantial beat on both GAAP revenue and non-GAAP earnings compared to Wall Street estimates. GAAP revenue reached $452 million, well above the $298.3 million analyst consensus. Ionis also raised its full-year 2025 revenue guidance by $100 million, driven by early commercial momentum for new products and a significant one-time licensing payment. Overall, the quarter showed major progress across commercial launches and strategic partnerships, though the sharp jump in profit was tied to nonrecurring events.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Ionis is a biotechnology company developing medicines based on RNA-targeted technology known as antisense. This technology allows Ionis to design drugs that can specifically block or alter the production of disease-related proteins at the genetic messaging (RNA) level. The approach enables it to address diseases that are difficult to treat using conventional drugs.
Source Fool.com
